Press Releases

May 29, 2020
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with at Least
May 06, 2020
Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 ALPHA2 Trial for ALLO-501A, the Next Generation anti-CD19 AlloCAR T™ Intended for Phase 2
Apr 29, 2020
Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T Therapy ALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion Platform Phase 1 Study Continues Enrollment to Optimize Lymphodepletion SOUTH SAN
Displaying 11 - 20 of 25
Print Page
Email Alerts
RSS Feeds
Investor Contacts